Andrea Necchi, Associate Professor at Università Vita-Salute San Raffaele, Director of Genitourinary Medical Oncology at Ospedale San Raffaele, shared a post on X:
“Pleased to share our next ASCO26 – Journal of Clinical Oncology Simultaneous Publication.
Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer SURE-01 Trial following our previous SURE02
29% pCR rate with monotherapy supports TROP2 as a reliable target in MIBC.
Biomarkers point to the Payload TOP1 effect rather than the Ab target.”
To which Emanuele Crupi, Post Doctoral Fellow at MD Anderson Cancer Center, Houston Medical Oncology Fellow at IRCCS San Raffaele, added:
“Now out on Journal of Clinical Oncology results of SURE-01 trial evaluating Neoadjuvant Sacituzumab Govitecan.
- Target: TROP2
- Warhead: SN-38 (Topoi)
The best way to start the breakfast before the session of DAY-3 of ASCO26.”
Title: Neoadjuvant Sacituzumab Govitecan in Patients With Muscle-Invasive Bladder Cancer: Primary Results of the SURE-01 Trial
Authors: Andrea Necchi, Joep J. de Jong, Brigida A. Maiorano, James A. Proudfoot, Giuseppe Basile, Antonio Cigliola, Chiara Mercinelli, Valentina Tateo, Michela Piacentini, Emanuele Crupi, Giovanni L. Pastorino, Gaia Latini, Enrico Tomasi, Elai Davicioni, Marco Moschini, Giorgio Brembilla, Maurizio Colecchia, Francesco de Cobelli, Jeffrey S. Ross, Russell Madison, Candice Francheska B. Tambaoan, Alberto Briganti, Francesco Montorsi.
Other articles feauturing Andrea Necchi and Emanuele Crupi on OncoDaily.